Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations - Phase 2 - Not yet recruiting
ongoing trials trial from other registries
Details- 2022
- Aceragen
Evaluation the effects of camel milk in spirometry parameters in over 6 yearâs children with Cystic Fibrosis lung disease - Recruiting
ongoing trials trial from other registries
Details- 2022
Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis - Phase 2 - Recruiting
ongoing trials trial from other registries
Details- 2022
- University of Kansas Medical Center
A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation
ongoing trials trial from other registries
Details- 2021
CYstic Fibrosis bacterioPHage Study at Yale (CYPHY) - Phase 1|Phase 2 - Not yet recruiting
ongoing trials trial from other registries
Details- 2021
- Yale University
Clinical trial of comparison between use of intravenous aminoglycosides versus intravenous and nebulize aminoglycosides in cystic fibrosis patients - Recruiting
ongoing trials trial from other registries
Details- 2021
Evaluation of the effectiveness of 7% plus hypertonic saline in comparison with 7% hypertonic saline in reducing the growth of Pseudomonas aeruginosa in lung of the patient with cystic fibrosis disease. - Recruiting
ongoing trials trial from other registries
Details- 2021
The effect of compound honey syrup on clinical manifestations of chronic sinusitis in cystic fibrosis (CF) patients - Recruiting
ongoing trials trial from other registries
Details- 2021
A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508delMutation and a Minimal Function Mutation (F/MF)
ongoing trials trial from other registries
Details- 2021
A randomized, open-label, active controlled, parallel group, multicenter phase 3 study to evaluate the efficacy and tolerability of Bamlanivimab and Etesevimab, Casirivimab and Imdevimab, and Sotrovimab versus Standard of Care in patients with mild to moderate COVID-19 disease (AntiCov)
ongoing trials trial from other registries
Details- 2021